BETAAccess all features while we're in beta! Some features may become paid later.Got feedback? Reach us 👉

Loading MYGN charts…

Search ticker or company⌘K

MYGN

01Multicharts 02Comparables 03Price target

May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy

MYGN · Myriad Genetics Inc. fundamentals · vpside

vpside

⌘K

MYGNMarket cap $601M/Last filing 10-Q, Q2 FY26 · 31 Jul 2026/MYGNMarket cap $601M/Last filing 10-Q, Q2 FY26 · 31 Jul 2026/MYGNMarket cap $601M/Last filing 10-Q, Q2 FY26 · 31 Jul 2026/MYGNMarket cap $601M/Last filing 10-Q, Q2 FY26 · 31 Jul 2026/

Filings synced 13:22 · Prices: prior close 30 Oct

MYGN

Myriad Genetics Inc.

Nasdaq · In vitro & in vivo diagnostic substances (SIC 2835) · FY ends 31 Dec

01Multicharts 02Comparables 03Price target

Add a metric37 metrics

Revenue, quarterly

$191M−10.5% year on year

$300M$200M$100M$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 31 Jul 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

68.8%−1.6 pp year on year

71%70%69%68%

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 31 Jul 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$115M+54.8% year on year

$300M$200M$100M$0

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 31 Jul 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$7M

$100M$0−$100M−$200M

vpside.com

Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26

Company filings · 10-Q filed 31 Jul 2026 · TTM = last four quartersvpside.com

Chart 05 is empty

Chart 06 is empty

Fundamentals: company filings · Q4 = full year − nine months · TTM = last four quarters